As atezolizumab is administered systemically, we evaluated the distribution of PD-L1 expression in major systemic immune cell lineages by high-dimensional flow cytometry in a small exploratory study with NSCLC patients undergoing PD-L1/PD-1 blockade. The gene discussed is CD274; the disease is non-small cell lung carcinoma.